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Abstract Hypoxia-inducible factor 1 (HIF-1) is a heterodi-
meric DNA-binding complex of the subunits K and L with
relevance in O2 and energy homeostasis. The labile component,
HIF-1K, is not only activated by hypoxia but also by peptides
such as insulin and interleukin-1 (IL-1) in normoxia. We
investigated whether inhibitors of mitogen-activated protein
kinase kinases (MAPKKs: PD 98059, U0126) and phosphati-
dylinositol 3-kinase (PI3K: LY 294002) do not only lower the
hypoxia-induced, but also the insulin- and IL-1-induced HIF-1K
accumulation and HIF-1 DNA-binding in human hepatoma cell
cultures (line HepG2). The results show that LY 294002
suppressed HIF-1 activation in a dose-dependent manner
irrespective of the stimulus. With respect to target proteins
controlled by HIF-1, the production of erythropoietin was fully
blocked and that of vascular endothelial growth factor reduced
following inhibition of the PI3K pathway. The role of MAPKKs
in this process remained in question, because PD 98059 and
U0126 did not significantly reduce HIF-1K levels at non-toxic
doses. We propose that PI3K signaling is not only important in
the hypoxic induction of HIF-1 but it is also crucially involved in
the response to insulin and IL-1. ß 2002 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Hypoxia-inducible factor 1 (HIF-1) is a dimeric (K/L) tran-
scription factor of major importance for the cellular adapta-
tion to O2 de¢ciency [1,2]. While the L-subunit of HIF-1 is
always available in the nucleus, the K-subunit is highly sus-
ceptible to O2 and undergoes rapid proteasomal degradation
under normoxic conditions. In the presence of O2 and iron,
proline residue 564 in HIF-1K is hydroxylated which enables
binding of the von Hippel-Lindau tumor suppressor E3 ligase
complex [3,4]. In hypoxia, the K- and L-subunits can dimerize
in the nucleus and bind to the consensus sequence (A)CGTG
present in the hypoxia response element of O2-controlled tar-
get genes such as those encoding vascular endothelial growth
factor (VEGF), erythropoietin (EPO) and distinct glycolytic
enzymes. Evidence suggests that the transcriptional activity of
HIF-1 is modulated by phosphorylation [5]. The p42/p44
(Erk2/Erk1) mitogen-activated protein kinases (MAPKs) can
catalyze HIF-1K phosphorylation [6^11], yielding larger mo-
lecular forms (V110 kDa) on electrophoretic separation [7].
The p42/p44 MAPK pathway does not seem to be involved in
the stabilization or degradation of HIF-1K but is likely to
increase the transactivation potential of the HIF-1 complex.
However, MAPKs do not appear to be activated by hypoxia
in general [7]. In addition, hypoxia exposure causes activation
of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway in
some cell lines [12^14]. Pharmacological blockade of PI3K
lowers HIF-1-dependent cellular responses to hypoxia [14^
16]. Endogenously, the product of the tumor suppressor
gene PTEN inhibits e¡ects of PI3K, as it encodes a phospha-
tase acting on D3 position phosphorylated phosphoinositides.
Loss of the tumor suppressor function of PTEN augments
HIF-1-mediated gene expression [17].
Recent studies have shown that HIF-1 is not only induced
by hypoxia, but is activated also in normoxic cells in response
to a variety of peptide mediators, including insulin and insu-
lin-like growth factors [18,19], interleukin-1 (IL-1) and tumor
necrosis factor K (TNFK) [20^22], angiotensin II [23] and
thrombin [24]. Upon binding of these mediators to their spe-
ci¢c membrane receptors various kinases are activated includ-
ing MAPKs and PI3K. The relevance of these pathways with
respect to HIF-1 needs to be further elucidated. In vascular
smooth muscle cells, the induction of HIF-1K by angiotensin
II is not abolished by inhibitors of p42/p44 MAPK kinases
(MAPKKs) or PI3K [23]. In contrast, inhibition of PI3K
signaling prevents the induction of HIF-1K in insulin-treated
human prostate carcinoma cell cultures [25]. Whether IL-1-
induced HIF-1 DNA-binding in normoxic cells involves
MAPK or PI3K recruitment is unknown.
Herein, e¡ects were studied of speci¢c inhibitors of
MAPKKs (PD 98059, U0126) and of the p110 subunit of
PI3K (LY 294002) on hypoxia-, insulin- and IL-1-induced
HIF-1K accumulation, HIF-1 DNA-binding, and VEGF as
well as EPO synthesis in a human hepatoma cell line
(HepG2) that is an established model for O2-dependent gene
expression [26].
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2. Materials and methods
2.1. Cell culture
HepG2 cells from the American Type Culture Collection (ATCC
no. HB 8065) were maintained in RPMI 1640 medium (Gibco BRL,
Karlsruhe, Germany) supplemented with 10% fetal bovine serum
(FBS; Sigma, Deisenhofen, or Life Technologies, Karlsruhe, Ger-
many), penicillin (90 U/ml) and streptomycin (90 Wg/ml) in a humidi-
¢ed atmosphere (5% CO2 in air) at 37‡C (Heraeus Incubators, Hanau,
Germany). For experiments cells were grown to 25^50% con£uence in
tissue culture dishes of 145 mm diameter (Greiner, Frickenhausen,
Germany). For studies with insulin, FBS-containing medium was re-
placed by serum-free medium with bovine serum albumin (BSA; 1 g/l)
at least 16 h before the experiments were started. For induction of
hypoxia dishes were placed in a humidi¢ed incubator with 3% O2, 5%
CO2 and 92% N2. Cells were treated with human insulin (stock solu-
tion 40 U/ml = 1.7 mg/ml; Aventis Pharma, Bad Soden, Germany) or
recombinant human IL-1L (Ciba-Geigy, Basel, Switzerland). The
MAPKK inhibitors PD 98059 (Calbiochem, Bad Soden, Germany)
[27] and U0126 (Promega, Heidelberg, Germany) [28] were dissolved
in dimethyl sulfoxide (DMSO) at 10 mM, stored in aliquots at 340‡C,
and diluted in culture medium to 9100 WM just prior to use. The
speci¢c PI3K inhibitor LY 294002 (Calbiochem) [29] was prepared
similarly. Cultures were pre-incubated with PD 98059 60 min and
with LY 294002 10 min prior to the experiments. The ¢nal DMSO
concentration was 5x in all cultures, including the controls. The
experimental incubation periods were 4 h, 6 h or 24 h, as speci¢ed.
In order to quantify cytotoxic drug e¡ects, the colorimetric tetrazo-
lium salt/formazan method was applied, which is based on the reduc-
tion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT; Sigma) to purple formazan in living cells. Con£uent HepG2
cultures in 96-well dishes were used for these studies as described [30].
2.2. Nuclear extract preparation
Cells were washed with ice-cold phosphate-bu¡ered saline (PBS),
harvested in 6 ml PBS, and centrifuged at 800Ug for 6 min at 4‡C.
The cell pellets were washed with 4 ml ice-cold bu¡er A (10 mM Tris,
pH 7.8, 1.5 mM MgCl2, and 10 mM KCl), resuspended in this bu¡er
and kept on ice for 10 min. Cell lysis was controlled by trypan blue
staining. Nuclei were pelleted at 3500Ug for 6 min at 4‡C, and re-
suspended in 100 Wl ice-cold bu¡er C (420 mM KCl, 20 mM Tris, pH
7.8, 1.5 mM MgCl2, and 20% glycerol) and incubated for 30 min on
ice with occasional £icking of the tubes. Just prior to use, both bu¡ers
were supplemented with 2 Wg/ml aprotinin, 10 Wg/ml leupeptin, 20 Wg/
ml pepstatin, 1 mM Na3VO4, 0.5 mM benzamidine, 2 mM levamisole,
10 mM L-glycerophosphate, 0.5 mM dithiothreitol (DTT), and 0.4
mM phenylmethylsulfonyl £uoride. Nuclei were centrifuged at
13 000Ug for 30 min at 4‡C. The supernatants were stored at
380‡C. Protein concentrations were determined by the Bradford
method using BSA as standard.
2.3. Western blot analysis
For determination of immunoreactive HIF-1K protein, nuclear ex-
tracts were subjected to Western blot analysis as described [20]. Sam-
ples were run on sodium dodecyl sulfate/7.5% polyacrylamide gels and
transferred to PVDF membranes (Roth, Karlsruhe, Germany). Equal
loading and transfer e⁄ciency was veri¢ed by staining with 2% Pon-
ceau S. Membranes were blocked overnight with PBS/5% fat-free skim
milk and then incubated for 1.5 h at room temperature with a 1:1000
diluted monoclonal mouse antibody against human HIF-1K (Trans-
duction Laboratories, Heidelberg, Germany). For detection, a horse-
radish peroxidase-linked anti-mouse IgG antibody (1:2000, 1 h at
room temperature; Santa Cruz, Heidelberg, Germany) and enhanced
chemiluminescence substrate (Amersham, Freiburg, Germany) were
used.
2.4. Electrophoretic mobility shift assay (EMSA)
Oligonucleotides for gel shift assays were synthesized by MWG
(Ebersberg, Germany). The sequences containing the HIF-1 binding
sites were derived from the human transferrin gene (TfHBS) accord-
ing to Rolfs et al. [31]. Sequences were: TfHBS (sense), 5P-
TTCCTGCACGTACACACAAAGCGCACGTATTTC-3P, and
TfHBS (antisense), 5P-GAAATACGTGCGCTTTGTGTGTACGTG-
CAGGAA-3P. After 5P end labeling of the sense strand unincorpo-
rated [Q-32P]-labeled ATP (New England Nuclear, Cologne, Germany)
was removed with a Sephadex G50 (Pharmacia, Uppsala, Sweden)
column. The annealing reaction was performed in the presence of a
two-fold molar excess of unlabeled antisense oligonucleotides and
1 mM MgCl2. Binding reactions were set up in a volume of 20 Wl.
Nuclear extracts (5 Wg of protein) were pre-incubated on ice for 30
min in a bu¡er containing 50 mM KCl, 10 mM Tris, pH 7.7, 5 mM
DTT, 1 mM EDTA, 1 mM MgCl2, 5% glycerol, 0.03% NP40, and 500
ng salmon testes DNA. Following the addition of the 32P-labeled
oligonucleotide, the reactions were incubated at 4‡C overnight. Sam-
ples were resolved by electrophoresis on native 5% polyacrylamide
gels at room temperature. Gels were dried and analyzed by phospho-
imaging (BAS 1000; Fuji, Du«sseldorf, Germany). For competition
experiments, a 250-fold molar excess of unlabeled annealed oligonu-
cleotide or an unspeci¢c unlabeled nucleotide (nuclear factor (NF)-UB
sequence) was added before the labeled probes. For supershift experi-
ments, 1 Wl undiluted anti-HIF-1K antibody (Transduction Laborato-
ries) was added 30 min before the gel was run.
2.5. Luciferase assay
HepG2 cells were stably transfected with a hypoxia-responsive re-
porter gene construct as described previously [32]. Brie£y, the ¢re£y
luciferase reporter gene plasmid pH3SVL [32], containing a total of
six HIF-1 binding sites derived from the transferrin gene, was linear-
ized with XmnI, mixed with the EcoRI-linearized neomycin expression
vector pSV2neo at a molar ratio of 10:1, and co-electroporated into
HepG2 cells. Following limited dilution and selection in 250^500 Wg/
ml G418 (PAA Laboratories, Co« lbe, Germany), a hypoxia reporter
cell line (termed HRG1) was chosen based on the e⁄ciency of hypoxic
reporter gene induction. HRG1 (4U104 cells per well ; 24-well; Nunc,
Wiesbaden, Germany) was seeded and grown for 48 h. Following 24 h
of hypoxic (3% O2) incubation in the absence or presence of kinase
inhibitors the cells were lysed (‘passive lysis’ ; Promega) and luciferase
activity measured in a MicroLumate LB 96P (Berthold EGpG, Bad
Wildbach, Germany).
2.6. Assay of VEGF and EPO
VEGF121=165 in the culture media was measured by commercial
enzyme-linked immunoassay (ELISA; Quantikine; RpD Systems,
Minneapolis, MN, USA). EPO was measured using a commercial
ELISA test kit calibrated against the World Health Organization
Standard Preparation (Medac, Hamburg, Germany). The rates of
the production of VEGF and EPO were related to cellular protein
as a measure of culture density. To this aim, the cultures were rinsed
with PBS, prior to the addition of lysis bu¡er (25 mM Tris, 1 mM
DTT, 1 mM EDTA, 15% glycerol, 1% Triton X-100; pH 7.8). Protein
was measured by the Bradford method. The results are given as the
mean þ S.D. Dunnett’s test was applied to determine the signi¢cance
of di¡erence (P6 0.05) between a control mean and several treatment
means and Tukey^Kramer’s test for multiple comparisons.
3. Results and discussion
HIF-1K protein was barely detectable on Western blots of
nuclear extracts from normoxic HepG2 cultures without spe-
ci¢c hormonal stimulation. However, on exposure to hypoxia
(4 h at 3% O2) signi¢cant amounts of HIF-1K were demon-
strated (Fig. 1A). The presence of DMSO (5x) in the culture
media did not alter the response to hypoxia. The addition of
the PI3K inhibitor LY 294002 produced a dose-dependent
decrease in the level of HIF-1K. The MAPKK inhibitor PD
98059 moderately lowered the level of HIF-1K, but there was
no clear dose-dependency. Likewise, U0126 moderately low-
ered HIF-1K levels in hypoxic HepG2 cultures at 10 WM,
while it was ine¡ective at 1 WM (Fig. 2A). Note that the
anti-HIF-1K antibody reacts with HIF-1K forms of varying
molecular mass, which may range from 104 to 116 kDa. There
is evidence that the high molecular forms arise as a product of
phosphorylation [7]. Accordingly, the high molecular forms of
HIF-1K were more strongly reduced by PD 98059 treatment.
This observation supported the concept that the p42/p44
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MAPK pathway is involved in the phosphorylation of HIF-
1K, while blockade of this pathway results in smaller forms of
HIF-1K [7]. Next, corresponding nuclear extracts from hy-
poxic HepG2 cultures were subjected to EMSA (Fig. 1B).
The HIF-1 DNA complex was dose-dependently lowered on
LY 294002 treatment, while PD 98059 exerted a smaller e¡ect
in hypoxic HepG2 cells. To test the functional relevance of the
lowered HIF-1K protein levels and HIF-1 DNA-binding, re-
porter gene assays were performed using the stably transfected
HepG2 subline HRG1. LY 294002 (v10 WM) produced a
signi¢cant decrease in relative luciferase activity when com-
pared to hypoxic control cells (P6 0.05, Dunnett’s test), in-
dicating that the PI3K pathway is involved in hypoxia-in-
duced HIF-1 activation (Fig. 1C). These ¢ndings are in line
with previous observations made on Ha-ras-transformed
NIH3T3R cells [12] and on human prostate cancer cell cul-
tures [16].
To view proteins encoded by HIF-1 target genes, e¡ects of
kinase inhibitors were studied on the 24 h rates of the pro-
duction of EPO and VEGF. In hypoxic control cultures, the
production of EPO amounted to 86 mU/mg cell protein
( þ 26; mean þ S.D., n = 5) and of VEGF to 39.0 ng/mg cell
protein ( þ 2.0; mean þ S.D., n = 4). These values were signi¢-
cantly reduced to 3 mU EPO/mg ( þ 4) and 31.6 ng VEGF/mg
( þ 1.6) in LY 294002 (50 WM)-treated cells. Upon PD 98059
(40 WM) treatment, EPO synthesis was unaltered (102 mU/
mg, þ 15), while that of VEGF was lowered to 22.8 ng/mg
( þ 0.5). To the best of our knowledge, e¡ects of the kinase
inhibitors on EPO synthesis have not been reported previ-
ously. In contrast, the inhibition of the production of
VEGF observed herein is in line with measurements of
VEGF expression at the mRNA and/or protein level in
NIH3T3R cells [12], human prostate TSU cancer cells [16]
and human breast cancer cells [33] following LY 294002 treat-
ment, and of VEGF mRNA in hamster CCL 39 ¢broblasts
following PD 98059 treatment [6]. In the human glioblastoma
cell line U87 MG PI3K inhibition by wortmannin lowers hyp-
oxia-induced VEGF mRNA expression, while PD 98059 does
not [34].
Taken together, our ¢ndings support the concept that HIF-
1K expression, HIF-1 DNA-binding and induction of HIF-1-
controlled proteins (EPO and VEGF) in response to hypoxia
depend on a functioning PI3K signaling pathway in HepG2
cells. Regarding the e¡ects of the MAPKK inhibitor PD
98059 a clear dose-dependency could not be established.
Here, it should be noted that few studies have considered
Fig. 1. A: Western blot analysis of HIF-1K in nuclear extracts of hypoxia-exposed (4 h at 3% O2) HepG2 cells treated with LY 294002 or PD
98059. Hypoxic control cultures were treated with DMSO only. B: Gel shift analysis with nuclear extracts of similarly treated cells. HIF-1, in-
ducible HIF-1 binding; const., constitutive binding; nonspec., non-speci¢c binding. C: Luciferase activities in the stably transfected hypoxia re-
porter cell line HRG1 maintained in normoxia (20% O2) or hypoxia (3% O2) (black bars) for 4 h. Results from normoxic cultures and hypoxic
cultures treated with LY 294002 were related to the activity of the hypoxic control cultures (100%). The ¢gure shows the mean þ S.D. of four
parallel cultures. Similar results were obtained in two additional independent experiments.
Fig. 2. A: Western blot analysis of HIF-1K in nuclear extracts of
normoxic and of hypoxic HepG2 cells treated with U0126 for 4 h.
B: Western blot analysis of HIF-1K in nuclear extracts of hypoxic
and normoxic HepG2 cells, and of normoxic cells treated with IL-
1L and U0126 for 4 h.
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the potential negative e¡ects of the kinase inhibitors on cell
viability. Based on MTT assay, LY 294002 was not toxic even
at the highest concentration tested (100 WM). In contrast, PD
98059 reduced formazan formation signi¢cantly at 100 WM
(by 11 þ 9%, n = 8) during 6 h incubation periods, and at 40
WM (by 14 þ 3%, n = 8) and 100 WM (by 16 þ 5%, n = 8) during
24 h of incubation (P6 0.05, Dunnett’s test). U0126 reduced
formazan formation signi¢cantly at 3 WM (by 10 þ 3%, n = 8)
during 6 h of incubation and at 1 WM (by 9 þ 4%, n = 8) dur-
ing 24 h of incubation (P6 0.05, Dunnett’s test). Interestingly,
a recent study has shown that the addition of PD 98059
causes marked DNA fragmentation and blocks the anti-apo-
ptotic e¡ects of hypoxia and VEGF in serum-deprived HepG2
cultures [35]. Furthermore, based on studies with the human
breast carcinoma cell line MCF-7 a model has been proposed
suggesting that dephosphorylated HIF-1K may activate the
p53-dependent apoptotic pathway [36].
The addition of insulin (dose range 20 WU/ml to 2 U/ml) to
normoxic HepG2 cultures resulted in a dose-dependent in-
crease in nuclear HIF-1K levels as determined by Western
blot analysis (Fig. 3A). In addition, insulin produced an in-
crease in HIF-1 DNA-binding (Fig. 3B), which con¢rms ¢nd-
ings by Zelzer et al. [18]. Furthermore, the production of
VEGF was measured to increase on insulin treatment (Fig.
4). Others have shown that insulin increases VEGF mRNA
levels in chicken embryo ¢broblasts and chorioallantoic mem-
brane-derived endothelial cells [15]. EPO production was un-
altered during the 6 h period of normoxic incubation. The
lack of stimulation of EPO production of normoxic HepG2
cells by insulin is in line with earlier studies [37]. Apparently,
an increase in the formation of HIF-1 DNA complex alone
does not su⁄ce to stimulate EPO gene expression in normoxic
human hepatoma cells.
Activation of PI3K and Akt are early events in insulin
signaling. Indeed, LY 294002 strongly suppressed HIF-1K ex-
pression in insulin-treated normoxic HepG2 cultures, while
PD 98059 was much less e¡ective (Fig. 5). Similar to the
action in hypoxic HepG2 cultures, inhibition of PI3K signal-
ing by LY 294002 completely blocked EPO production in
normoxic HepG2 cells treated with insulin (Table 1). PD
98059 moderately reduced EPO production. However, like
in hypoxic HepG2 cultures, PD 98059 was more potent
than LY 294002 in lowering VEGF synthesis in insulin-
treated HepG2 cells (Table 1). Previous studies have shown
that LY 294002 inhibits insulin-induced VEGF mRNA ex-
pression in chicken chorioallantoic endothelial cells but not
in chicken embryo ¢broblasts [15]. Wortmannin prevents the
e¡ect of insulin in NIH3T3 ¢broblasts while PD 98059 is not
inhibiting in this model [38]. Apparently, there is tissue-spe-
ci¢city in the potential of the kinase inhibitors to modulate
Fig. 3. A: Western blot analysis of HIF-1K in nuclear extracts of
hypoxic, normoxic, and normoxic HepG2 cells treated with insulin
for 4 h. B: Gel shift analysis with nuclear extracts of similarly
treated cells (for abbreviations, see Fig. 1). Speci¢city was con¢rmed
in competition experiments with a 250-fold molar excess of unla-
beled annealed TfHBS oligonucleotide, the unspeci¢c NF-UB oligo-
nucleotide and in a supershift experiment with anti-HIF-1K antibod-
ies (Ab) with nuclear extracts from hypoxic HepG2 cells.
Fig. 4. E¡ects of insulin treatment on the production of immunore-
active VEGF by normoxic HepG2 cultures during 6 h incubation
periods (mean þ S.D. of four parallel cultures).
Fig. 5. Western blot analysis of HIF-1K in nuclear extracts of nor-
moxic HepG2 cultures treated with insulin (0.2 U/ml) in the absence
(DMSO) or presence of LY 294002 or PD 98059 (4 h incubation).
A control without insulin is also shown.
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insulin-induced VEGF mRNA expression and VEGF synthe-
sis.
In contrast to hypoxia or insulin, IL-1 does not signi¢cantly
stimulate VEGF production in HepG2 cultures, although this
cytokine increases HIF-1 DNA-binding [20]. Moreover, IL-1
lowers EPO gene expression in hypoxic HepG2 cells [39]. The
present studies show that IL-1L-induced HIF-1K accumula-
tion in nuclei of normoxic HepG2 cells was dose-dependently
blocked by LY 294002, while PD 98059 (Fig. 6A) or U0126
(Fig. 2B) were not e¡ective in non-toxic concentrations. In
addition, LY 294002 suppressed the formation of the HIF-1
DNA complex as studied by EMSA (Fig. 6B). E¡ects of ki-
nase inhibitors on IL-1-induced HIF-1 activation have not
been studied previously. The biological meaning of the e¡ect
of IL-1 on HIF-1 DNA-binding needs to be further investi-
gated, although it has been implicated in VEGF production in
human proximal tubular cells [21] and synovial ¢broblasts
[22].
In conclusion, the present ¢ndings show that the PI3K/Akt
signaling pathway is essential in the accumulation of HIF-1K
and HIF-1 DNA complex in response to hypoxia, insulin and
IL-1 in HepG2 cells. The role of MAPKs in this process is still
in question. Regarding the normoxic activation of HIF-1 by
insulin and IL-1 it seems worthy to follow the recent concept
that the PI3K/Akt pathway is important for HIF-1K stabili-
zation, while MAPKs increase the transactivation activity of
HIF-1K [5,40]. Also, our studies do not preclude the existence
of other pathways of activation of HIF-1, as has been shown
for angiotensin II, which is thought to increase HIF-1K levels
via the formation of reactive O2 species, ROS [23]. Studies
utilizing rat lung epithelial cells indicate that the activation
of HIF-1 by TNFK is also mediated by ROS [41]. However,
the rates of transcription of the VEGF and EPO genes are
controlled by transacting factors other than HIF-1. Like
many other cell lines [42], normoxic HepG2 cells exhibit a
high level of VEGF mRNA [20] that is only little increased
by hypoxia. Accordingly, LY 294002 did not inhibit VEGF
synthesis in normoxic HepG2 cells and exerted only a mod-
erate inhibition in hypoxic cultures, despite the decrease in
HIF-1 DNA-binding. In contrast, EPO synthesis seems to
be more strictly HIF-1-dependent. EPO production was al-
most completely suppressed on LY 294002 treatment along
with the loss of nuclear HIF-1K accumulation, HIF-1 DNA-
binding and reporter gene activity.
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